Incyte Corporation's stock (NASDAQ: INCY) declined by 3.43% as part of a broader market trend affecting growth stocks amid concerns about rising interest rates and potential economic downturns, impacting investor sentiment and valuations.

Incyte Corporation's stock (NASDAQ: INCY) declined by 3

Incyte (INCY) stock rose 10.28% due to improved investor sentiment driven by strong performance in healthcare and pharmaceuticals, alongside overall positive market trends despite concerns over trade negotiations.

Incyte (INCY) stock rose 10

Incyte Corporation's stock (NASDAQ: INCY) fell by 0.41% following a significant reduction in stake by Y Intercept Hong Kong Ltd, which sold off over half of its shares, causing concern among investors amid ongoing adjustments in institutional holdings and mixed analyst ratings.

Incyte Corporation's stock (NASDAQ: INCY) fell by 0

Incyte Corporation (NASDAQ:INCY) stock recently fell by 0.28%, influenced by insider selling activity, including significant shares sold by executives, as well as mixed analyst ratings and price targets that may have affected investor sentiment.

Incyte Corporation (NASDAQ:INCY) stock recently fell by 0

Incyte Corporation's stock (NASDAQ: INCY) rose by 2.26% following positive quarterly earnings results that exceeded consensus estimates, reflecting strong revenue growth and increased investor interest despite some recent insider selling.

Incyte Corporation's stock (NASDAQ: INCY) rose by 2

Incyte Corporation's (NASDAQ: INCY) stock fell by 0.42% after analysts at William Blair revised their Q2 2025 earnings per share estimates downward from $1.11 to $1.06, contributing to market concerns about the company's financial outlook.

Incyte Corporation's (NASDAQ: INCY) stock fell by 0

Incyte Corporation (NASDAQ: INCY) saw a 1.44% increase in its stock price after institutional investors, including Cerity Partners LLC, significantly raised their holdings, indicating growing confidence in the company.

Incyte Corporation (NASDAQ: INCY) saw a 1

Incyte (NASDAQ: INCY) saw its stock rise by 1.44% following a mix of analysts adjusting their ratings and target prices, with notable support coming from quarterly earnings that exceeded expectations and a solid year-over-year revenue increase despite a price target reduction by JPMorgan Chase from $68 to $67, indicating potential confidence among investors in the company's performance.

Incyte (NASDAQ: INCY) saw its stock rise by 1

The article compares Eli Lilly and AbbVie, indicating Eli Lilly's stock has more favorable characteristics; however, Incyte (INCY) stock was down by -2.47% likely due to broader market trends or investor sentiment following developments in the pharmaceutical sector that may influence valuations or earnings expectations.

The article compares Eli Lilly and AbbVie, indicating Eli Lilly's stock has more favorable character

Incyte (INCY) stock fell by 2.47% due to negative market sentiment possibly influenced by broader economic factors and investor concerns in the biotech sector amidst ongoing global economic uncertainties.

Incyte (INCY) stock fell by 2

Incyte Corporation's stock (INCY) rose by 2.36% due to recent analyst upgrades, including a "buy" rating from Stifel Nicolaus and positive quarterly earnings results that exceeded expectations.

Incyte Corporation's stock (INCY) rose by 2

Incyte Corporation's stock (NASDAQ: INCY) increased by 1.55% amidst a backdrop of recent strong earnings results and substantial investments from large institutional investors, despite some mixed analyst ratings and insider selling. The stock's rise can be attributed to the company's better-than-expected quarterly earnings report and positive revenue growth, which likely reassured investors about its financial health and prospects.

Incyte Corporation's stock (NASDAQ: INCY) increased by 1

Incyte Corporation (NASDAQ:INCY) stock rose by 0.59% following the sale of shares by EVP Vijay K. Iyengar and strong quarterly earnings that exceeded analysts' expectations, indicating potential investor confidence.

Incyte Corporation (NASDAQ:INCY) stock rose by 0

Incyte Corporation (INCY) stock rose by 0.59% following a strong quarterly earnings report, which showed earnings per share exceeding expectations and revenue growth of 19.5%, despite an executive selling a significant portion of their shares.

Incyte Corporation (INCY) stock rose by 0

Incyte (INCY) stock increased by 0.59% amid mixed changes in institutional investments, with significant activities including a 16.8% reduction in holdings by Vontobel Holding Ltd. and several hedge funds boosting their stakes, reflecting a dynamic investment climate. The increase may be attributed to positive quarterly earnings, surpassing expectations, and continued confidence from some analysts giving favorable ratings and price targets for the stock.

Incyte (INCY) stock increased by 0

Incyte Corporation (NASDAQ:INCY) stock decreased by 1.72% following a significant reduction in stake by Allspring Global Investments Holdings LLC, which sold 135,764 shares during the first quarter, indicating potential investor concerns about the company's outlook and recent price adjustments by various analysts.

Incyte Corporation (NASDAQ:INCY) stock decreased by 1

The article discusses that Incyte Corporation's stock (NASDAQ: INCY) rose by 0.41%, attributed to significant increases in holdings by institutional investors, such as Sumitomo Mitsui Trust Group Inc., which raised its stake in the company.

The article discusses that Incyte Corporation's stock (NASDAQ: INCY) rose by 0

Incyte (INCY) stock rose 0.93% following the CEO's recent exercise of stock options, as detailed in a Form 4 filing, indicating confidence in the company's future prospects.

Incyte (INCY) stock rose 0

Incyte Corporation (NASDAQ:INCY) stock was down by -0.39% following speculation about its potential as an M&A target under new CEO Bill Meury, amid concerns over the impending loss of exclusivity for its key drug Jakafi, which could significantly impact earnings.

Incyte Corporation (NASDAQ:INCY) stock was down by -0

Incyte Corporation (NASDAQ: INCY) experienced a 3.45% decline in its stock price, attributed to a mix of analyst target price adjustments and sentiment influenced by institutional investor movements, despite favorable earnings reports.

Incyte Corporation (NASDAQ: INCY) experienced a 3

Incyte Corporation (NASDAQ: INCY) experienced a 3.45% decline in its stock value, attributed to a mix of rating downgrades from various analysts and ongoing market adjustments despite positive earnings results from the previous quarter.

Incyte (INCY) stock rose 4.83% following the announcement that Bill Meury would succeed Hervé Hoppenot as CEO, who is retiring after 11 years. The stock's increase is attributed to investor confidence in Meury's leadership, given his previous experience as CEO of other pharmaceutical companies.

Incyte (INCY) stock rose 4

Incyte Corporation's stock (NASDAQ: INCY) rose 4.83% following a significant increase in institutional investment, particularly by Wealth Enhancement Advisory Services LLC, which boosted its holdings in the company by 66.5% in the first quarter.

Incyte Corporation's stock (NASDAQ: INCY) rose 4

Incyte Corporation's stock (INCY) rose 4.83% following increased investments from institutional investors, including a notable 3.2% lift by the State of Alaska Department of Revenue and significant raises by Wells Fargo and other funds, alongside positive earnings results that exceeded analyst expectations.

Incyte Corporation's stock (INCY) rose 4

Incyte (INCY) stock rose 4.83% following the appointment of Bill Meury as the new CEO, replacing retiring Herve Hoppenot, which has fueled investor optimism regarding potential mergers and acquisitions.

Incyte (INCY) stock rose 4.83% following the announcement of Bill Meury's appointment as the new CEO, replacing retiring Hervé Hoppenot, which investors view as a positive leadership change aimed at enhancing the company’s R&D and growth strategy.

Incyte (INCY) stock increased by 0.28% due to significant institutional investments, including a 37.6% increase in holdings by Assenagon Asset Management and other large investors boosting their stakes, alongside positive earnings results that exceeded analysts' expectations.

Incyte Corporation (INCY) experienced a 0.78% decrease in stock value, potentially due to recent mixed analyst ratings and a general market trend, despite positive earnings and revenue growth.

Incyte Corporation (INCY) experienced a 0

Incyte (NASDAQ:INCY) stock fell by 0.78% despite an upgrade from Stifel Nicolaus to a "buy" rating and an increased price target due to mixed analyst sentiments and recent fluctuations in price targets from various firms. 

The stock may have declined as a result of varied analyst ratings, potential profit-taking after the upgrade, or reaction to a broader market trend rather than a specific negative event for Incyte itself.

Incyte (NASDAQ:INCY) stock fell by 0

Incyte (INCY) stock fell by 0.27% after a series of mixed analyst ratings and target price adjustments, along with a notable insider sale by an executive which may have raised concerns among investors.

Incyte (INCY) stock fell by 0

The article reports that Incyte (INCY) stock rose by 0.46% due to the acceptance of a New Drug Application (NDA) for the combination therapy of fruquintinib and sintilimab for treating advanced renal cell carcinoma in China, which signals potential market expansion and new treatment options in oncology.

The article reports that Incyte (INCY) stock rose by 0

Incyte (INCY) stock rose by 0.46% due to favorable analyst ratings, including UBS's neutral rating and upgrades from various brokerages, as well as strong earnings performance that exceeded consensus estimates.

Incyte (INCY) stock rose by 0

Incyte (INCY) stock increased by 1.71% following a price target increase from Truist Financial, which raised its target from $72.00 to $73.00, indicating a potential upside of 12.43% from the previous close.

Incyte (INCY) stock increased by 1

Incyte (INCY) stock recently experienced a decline of 0.8%, attributed to a combination of insider selling activity, where executives reduced their positions, and a series of downgrades and reduced price targets by various analysts.

Incyte (INCY) stock recently experienced a decline of 0

Incyte Co. (NASDAQ:INCY) experienced a 0.8% decline in its stock price amid analysts' mixed ratings and recent price target adjustments, including cuts from Morgan Stanley and JPMorgan Chase. The decline may stem from ongoing changes in analysts' sentiments and stock sales by company insiders.

Incyte Co

Incyte Co. (NASDAQ:INCY) stock saw a 0.79% increase due to significant investments from institutional investors, including a 249.9% increase in holdings by Focus Partners Wealth, alongside positive earnings results that exceeded analysts' expectations.

Incyte (INCY) stock increased by 0.79% due to significant interest from institutional investors acquiring new positions and increasing their stakes in the company, alongside positive quarterly earnings results that exceeded analysts' expectations.

Incyte (INCY) stock rose by 2.62% due to strong quarterly earnings that exceeded analysts' expectations, showing a 19.5% increase in revenue year-over-year, alongside involvement and adjustments by institutional investors in their shareholdings.

Incyte (INCY) stock rose by 2

The article discusses the importance of low-debt stocks for safety and investment potential, highlighting several companies including Incyte (INCY), which has seen a decline of 0.67% recently; the drop in its stock could be attributed to broader market fluctuations and the struggles faced by growth stocks amidst uncertain economic conditions.

The article discusses the importance of low-debt stocks for safety and investment potential, highlig

Incyte (INCY) stock rose 0.81% after a phase I study reported that their monoclonal antibody AMG 404, targeting programmed cell death-1, demonstrated promising safety and preliminary antitumor activity in patients with advanced solid tumors.

Incyte (INCY) stock was up 0.61% as it prepares to release its Q1 2025 earnings, with analysts anticipating earnings of $1.01 per share and revenue of $996.17 million, which may have contributed to investor optimism and the stock's rise.

Incyte (INCY) stock was up 0

Incyte (INCY) stock rose by 1.08% despite analysts from JPMorgan Chase lowering its price target from $70 to $68, demonstrating potential upside driven by investor interest despite mixed analyst ratings and recent insider sales.

Incyte (INCY) stock rose by 1

Incyte Co. (NASDAQ: INCY) stock rose by 1.08% due to a generally stable consensus rating of "Hold" from analysts, along with mixed recent price target adjustments from various research firms, indicating a cautiously optimistic outlook amid recent insider sales and institutional investment activity.

Incyte (INCY) stock rose by 1.02% due to positive comparisons made by analysts between MacroGenics and Ensysce Biosciences, highlighting MacroGenics' favorable outlook, which may bolster investor confidence in related stocks in the biopharmaceutical sector.

Incyte Corporation (NASDAQ: INCY) saw a 0.83% increase in its stock price, despite a reduction in Q1 2025 earnings estimates by William Blair and a miss on previous earnings expectations, as boosted institutional investments and analysts maintaining a "hold" rating may have contributed to positive market sentiment.

Incyte Corporation (NASDAQ: INCY) saw a 0

Incyte (INCY) stock rose by 0.83% due to strong institutional ownership and favorable analyst views indicating potential growth, as evidenced by comparative evaluations with other biotech firms like Exelixis and Agenus.

Incyte (INCY) stock rose by 3.08% last night due to positive overall market conditions driven by a pause on U.S. tariffs, which improved global sentiment and economic outlook, boosting investor confidence across various sectors.

Incyte (INCY) stock rose by 3

Incyte (INCY) stock fell by 5.51% likely due to investor concerns following the negative performance indicators and comparison to more established companies like Eli Lilly, which is perceived to have stronger financials and higher potential upside based on analyst recommendations.

Incyte (INCY) stock fell by 5

Incyte Corporation's stock (INCY) experienced a decline of 0.48% amid a backdrop of increased institutional investment, insider selling, and mixed analyst ratings, highlighting a possible lack of investor confidence and concerns over recent earnings performance.

Incyte Corporation's stock (INCY) experienced a decline of 0

Incyte (NASDAQ:INCY) stock declined by 1.11% amidst a backdrop of mixed analyst ratings and notable insider selling, indicating potential investor uncertainty and profit-taking.

Incyte (NASDAQ:INCY) stock declined by 1

Incyte (INCY) stock rose by 2.21% following an increase in earnings per share (EPS) estimates for FY2025 by analysts at William Blair, who now project earnings of $4.21 per share, slightly higher than previous estimates, despite a recent quarterly earnings miss.

Incyte (INCY) stock rose by 2.21% last night despite recent declines due to less favorable news from a clinical trial, possibly indicating a rebound or renewed investor interest despite previous concerns.

Incyte (INCY) stock increased by 0.4% despite being downgraded by William Blair from "outperform" to "market perform," likely due to other brokerages raising their price targets and maintaining hold or equal weight ratings, which may have instilled confidence among investors.

HUTCHMED and Innovent announced successful results from the FRUSICA-2 Phase II/III clinical trial concerning a combination treatment for advanced renal cell carcinoma, which may have contributed to a 0.57% increase in Incyte (INCY) stock due to positive investor sentiment surrounding the efficacy of this new therapy.

HUTCHMED and Innovent announced successful results from the FRUSICA-2 Phase II/III clinical trial co

Incyte (INCY) stock rose by 0.57% following a series of analyst rating adjustments, including Guggenheim's downgrade to neutral, but with a maintained price target of $92, suggesting mixed investor sentiment about the stock's potential. The rise in stock price could be attributed to potential investor optimism and interest despite the recent downgrades, as well as strategic insider trading and the overall market dynamics for healthcare stocks.

Incyte (INCY) stock rose by 0.57% despite a reduction in its price target by Truist Financial from $74.00 to $72.00 and several downgrades from other analysts, indicating potential modest investor optimism or confidence amidst the mixed ratings.

Incyte (INCY) stock dropped more than 10% after the company reported disappointing clinical trial results for its oral treatment for hidradenitis suppurativa (HS).

Incyte (INCY) stock dropped more than 10% after the company reported disappointing clinical trial re

Incyte (INCY) stock fell by 8.62% due to an analyst's assessment that its skin disease treatment, while viable, is not competitive with existing biologic therapies.

Incyte (INCY) stock fell by 8

Incyte Corporation's stock (NASDAQ: INCY) dropped by 8.62% following the release of topline results from its pivotal Phase 3 STOP-HS clinical trial for povorcitinib, which may not have met investor expectations or demonstrated sufficient efficacy or safety.

Incyte Corporation's stock (NASDAQ: INCY) dropped by 8

The article discusses the positive results of a study on Incyte Corporation's drug baricitinib for treating adolescent patients with severe alopecia areata, yet Incyte’s stock fell by 4.3%. The decline in Incyte (INCY) stock may be attributed to overall market conditions or investor sentiment, which often reacts to broader factors beyond just the study results, such as profit-taking or concerns about future sales performance.

The article discusses the positive results of a study on Incyte Corporation's drug baricitinib for t

The article compares Cortexyme (CRTX) and Agenus (AGEN) as investment options, noting that Cortexyme has higher earnings but lower revenue, and also highlights institutional ownership as a positive indicator for both stocks, with Agenus having a stronger consensus rating among analysts. Incyte (INCY) stock likely went up due to positive sentiment and strength in institutional ownership and earnings reports in the biotechnology sector.

INCY

Latest News & Analysis